$TSHA

Taysha Gene Therapies, Inc.

CIK:0001806310|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Revenue	$ 0	$ 1,986	$ 0	$ 4,288
Operating expenses:
Research and development	38,636	20,141	72,445	35,706
General and administrative	12,146	8,598	21,823	16,756
Net gain on lease termination	(3,433)	0	(3,433)	0
Total operating expenses	47,349	28,739	90,835	52,462
Loss from operations	(47,349)	(26,753)	(90,835)	(48,174)
Other income (expense):
Change in fair value of warrant liability	0	(273)	0	(171)
Change in fair value of term loan	(1,521)	(1,461)	(2,991)	(2,991)
Interest income	2,325	1,859	4,911	3,185
Interest expense	(6)	(17)	(15)	(36)
Other expense	(88)	(237)	(119)	(224)
Total other income (expense), net	710	(129)	1,786	(237)
Net loss	$ (46,639)	$ (26,882)	$ (89,049)	$ (48,411)
Net loss per common share, basic	$ (0.13)	$ (0.09)	$ (0.24)	$ (0.17)
Net loss per common share, diluted	$ (0.13)	$ (0.09)	$ (0.24)	$ (0.17)
Weighted average common shares outstanding, basic	369,044,040	297,988,978	367,845,094	283,726,888
Weighted average common shares outstanding, diluted	369,044,040	297,988,978	367,845,094	283,726,888

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities
Net loss	$ (89,049)	$ (48,411)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	586	560
Stock-based compensation	11,357	6,484
Non-cash net gain on lease termination	(5,108)
Change in fair value of warrant liability		171
Non-cash change in fair value of term loan	115	441
Non-cash lease expense	556	647
Other	123	236
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(1,439)	(570)
Accounts payable	5,846	3,921
Accrued expenses and other liabilities	(4,290)	(1,393)
Deferred revenue		(4,288)
Net cash used in operating activities	(81,303)	(42,202)
Cash flows from investing activities
Purchase of research and development license	(3,000)
Purchase of property, plant and equipment	(23)	(380)
Other		71
Net cash used in investing activities	(3,023)	(309)
Cash flows from financing activities
Proceeds from issuance of common stock and pre-funded warrants from underwritten public offering, net of underwriting discounts and sales commissions and other offering costs	216,139	216,170
Payment of shelf registration costs		(47)
Proceeds from common stock issuances under ESPP	176	75
Proceeds from stock option exercises	957
Other	94	38
Net cash provided by financing activities	217,366	216,236
Net increase in cash, cash equivalents and restricted cash	133,040	173,725
Cash, cash equivalents and restricted cash at the beginning of the period	322,531	141,636
Cash, cash equivalents and restricted cash at the end of the period	455,571	315,361
Cash and cash equivalents	455,407	312,761
Restricted cash	164	2,600
Supplemental disclosure of cash flow information:
Cash paid for interest	2,890	2,586
Supplemental disclosure of noncash investing and financing activities:
Property, plant and equipment in accounts payable and accrued expenses	243
Offering costs not yet paid	$ 378	$ 411

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 455,407	$ 319,767
Restricted cash	0	449
Prepaid expenses and other current assets	6,027	4,431
Total current assets	461,434	324,647
Restricted cash	164	2,315
Property, plant and equipment, net	2,412	6,736
Operating lease right-of-use assets	6,317	9,439
Other non-current assets	106	183
Total assets	470,433	343,320
Current liabilities
Accounts payable	9,164	6,275
Accrued expenses and other current liabilities	16,811	20,277
Total current liabilities	25,975	26,552
Term loan, net	49,260	50,106
Operating lease liability, net of current portion	6,291	18,172
Other non-current liabilities	1,641	1,552
Total liabilities	83,167	96,382
Commitments and contingencies - Note 13
Stockholders' equity
Preferred stock, $0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of June 30, 2026 and December 31, 2025
Common stock, $0.00001 par value per share; 700,000,000 shares authorized and 325,302,280 and 285,051,648 issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	3	3
Additional paid-in capital	1,186,843	958,427
Accumulated other comprehensive income (loss)	769	(192)
Accumulated deficit	(800,349)	(711,300)
Total stockholders' equity	387,266	246,938
Total liabilities and stockholders' equity	$ 470,433	$ 343,320